TRexBio Announces Pricing of Initial Public Offering
The offering is expected to provide approximately $116.7 million before underwriting discounts, commissions and other offering expenses.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TRexBio (TRXB) priced its initial public offering of common stock at $14.00 per share, with all shares offered by the company. The offering comprises 8,333,334 shares and is expected to generate approximately $116.7 million in gross proceeds before underwriting discounts, commissions and other offering expenses.
Trading is expected to begin on the Nasdaq Global Select Market on October 9, 2026. Closing is expected on October 13, 2026, subject to customary closing conditions. Underwriters have a 30-day option to purchase up to an additional 1,250,000 shares at the IPO price, less underwriting discounts and commissions.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.IPO funding is expected to generate approximately $116.7 million in gross proceeds before offering deductions.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.8,333,334 new common shares at $14.00 each dilute existing holders.
- Minor point. Forward-looking: it has not happened yet and may not happen.Underwriters’ 30-day option for up to 1,250,000 additional shares creates potential further dilution.
- Minor point. Forward-looking: it has not happened yet and may not happen.Underwriting discounts, commissions and other offering expenses reduce proceeds available to TRexBio.
News Explained
TRexBio is offering all 8,333,334 IPO shares; if issued, they would increase the share count and reduce existing holders’ percentage ownership absent offsetting changes, while closing remains expected on
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced the pricing of its initial public offering of 8,333,334 shares of its common stock at an initial public offering price of
J.P. Morgan, Evercore ISI, Cantor, and Stifel are acting as lead book-running managers for the offering. Wedbush PacGrow is acting as book-running manager for the offering.
A registration statement (File No. 333-299018) relating to the shares being sold in the offering has been filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on October 8, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from: J.P. Morgan Securities LLC, Attention Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; and Evercore Group L.L.C., 55 East 52nd Street, 35th Floor, New York, New York 10055, Attention: Equity Capital Markets, or by email at ecm.prospectus@evercore.com or by telephone at (888) 474-0200.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About TRexBio
TRexBio is a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio’s Deep Biology Platform decodes Treg functionality in human tissue, mapping key drivers of immune dysregulation and uncovering novel targets and insights that inform drug discovery and translational efforts. This platform has generated multiple therapeutic development candidates across TRexBio’s wholly owned pipeline and through collaborations with leading pharmaceutical partners. TRexBio is led by an experienced management team and headquartered in South San Francisco, California.
Forward-Looking Statements
This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the completion, timing, and size of the initial public offering and the commencement of trading on the Nasdaq Global Select Market. Each forward-looking statement is subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the initial public offering discussed above will be completed on the terms described or at all. Completion of the proposed initial public offering and the terms thereof are subject to numerous factors, many of which are beyond the control of TRexBio, including, without limitation, market conditions, failure of customary closing conditions, and the factors discussed in the “Risk Factors” section of the prospectus that forms a part of the registration statement, in the form last filed with the SEC. These forward-looking statements speak only as of the date of this press release and TRexBio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts Investors: Laura Berner, Chief Operating Officer, TRex Bio, Inc., info@trex.bio Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much is TRexBio raising in its IPO and at what price?
TRexBio expects approximately $116.7 million in gross proceeds from offering 8,333,334 common shares at $14.00 each. All shares are offered by the company. Gross proceeds exclude underwriting discounts, commissions and other offering expenses.
When will TRXB begin trading and when will the IPO close?
TRXB is expected to begin trading on the Nasdaq Global Select Market on October 9, 2026, with the IPO expected to close on October 13, 2026. Closing remains subject to customary closing conditions.